BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BioBlocks, Inc. and Emerald Bio Align to Speed and Streamline Discovery of Small-Molecule Drugs


1/8/2013 10:11:55 AM

SAN DIEGO, CA and BEDFORD, MA – January 8, 2013 - BioBlocks, Inc., an emerging leader in fragment-based lead discovery, and Emerald Bio, a protein and structural biology service provider, are working together to streamline clients’ access to expertise that will accelerate lead discovery and generate high-quality, small-molecule drugs in a cost effective manner.

BioBlocks’ Leap-to-LeadTM platform joined with Emerald Bio’s biophysical screening and structural biology capabilities, which use co-crystallization, nuclear magnetic resonance and other methodologies, provides clients with extensive, fully integrated, fragment-based, target-to-lead generation services.

“As the drug-discovery marketplace changes, our strategic alignment will enable more reliable external research because both companies are focused on streamlining processes based on our proprietary expertise, deep investments into orthogonal capabilities, and similar business cultures,” said Johan Pontin, Emerald Bio’s chairman and chief executive officer. “Together we look forward to offering our clients the ability to increase the probability of success for their drug discovery projects.”

“Despite recent advances in drug discovery technologies, the identification of leads that are ultimately successful in clinical trials remains a challenge,” said Peter Pallai, Ph.D., BioBlock’s president and chief executive officer. “Our Leap-to-Lead™ platform addresses this problem using physical and virtual fragment-based approaches, which provide a dynamic lead-development pathway. Combined with Emerald Bio’s critical structural insights, we are well positioned to generate high quality leads for our clients, including against difficult targets.”

About BioBlocks

Founded in San Diego in 2002, BioBlocks provides medicinal chemistry expertise and products to partners in the drug discovery community. In numerous collaborations aided by a results-based lead optimization model, BioBlocks scientists have developed preclinical candidates and reached program milestones. The Company’s Leap-to-Lead™ platform addresses fundamental issues in drug discovery – the high attrition rate and lack of novelty found in typical HTS hits – by providing an alternative source for high quality tractable leads with multiple possible optimization pathways. For more information on BioBlocks’ lead discovery services please visit www.bioblocks.com.

About Emerald Bio

Emerald Bio is a protein solutions provider offering consultative services, instrumentation, reagents, and software to help solve our client’s challenges in protein science. We leverage our unique assets and know-how in biochemistry and structural biology to improve our clients’ understanding of proteins, and that ultimately leads to better human health. Emerald Bio is a 2 privately owned company with facilities in Seattle and Boston. We support leading research institutes and commercial therapeutic and diagnostic companies worldwide. www.embios.com.

Contacts:

BioBlocks:

Peter Pallai, Ph.D.

President and Chief Executive Officer

858-558-5900

PPallai@bioblocks.com

www.bioblocks.com

Emerald Bio:

Mary A. C. Fallon,

Communications Consultant for Emerald Bio

408-499-4063

mary@critcom.com

www.embios.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->